Argenx Discontinued Phase 3 Sjögren's Disease Trial
A clinical trial for the treatment of moderate-to-severe Sjögren's disease has been halted for futility.
Updated on Oct. 8, 2026 in Arthritis
Live Poll
Do you trust pharmaceutical companies to prioritize patient health outcomes over successful clinical trial results?
Argenx has discontinued its Phase 3 UNITY study of the drug efgartigimod for patients with moderate-to-severe Sjögren's disease. The decision follows a recommendation from an Independent Data Monitoring Committee after the study failed to meet its primary endpoint.
Why it matters
This trial halt represents a setback for potential new therapies in the management of Sjögren's disease, a chronic condition that disproportionately affects women at a 9:1 ratio compared to men. It underscores the challenges of meeting specific clinical endpoints in autoimmune treatment research.
In the Phase 3 UNITY study, patients were randomized 1:1 to receive either efgartigimod SC or a placebo. The trial was stopped due to futility after an interim analysis determined the drug failed to meet its primary endpoint.
The players
Argenx
An Amsterdam-based biotechnology company focused on developing therapies for severe autoimmune diseases.
Independent Data Monitoring Committee
An external group of experts tasked with reviewing trial data to ensure participant safety and study efficacy.
The details
The UNITY trial evaluated efgartigimod, which was designed to address the underlying autoimmune activity of Sjögren's disease. While the study was stopped, safety results were consistent with the established profile of the drug, and researchers reported that no new safety signals were identified during the trial period.
Timeline
October 8, 2026: Argenx announced the discontinuation of the UNITY study.
Health Landscape
This decision represents a notable shift in the development trajectory for efgartigimod, which has been investigated across multiple autoimmune indications. The outcome highlights the difficulty of addressing the complex, multisystem nature of Sjögren's disease compared to other conditions.
For patients currently managing Sjögren's disease, this study result does not change existing treatment options or standard care protocols. Any concerns regarding current management plans or interest in future clinical trial participation should be addressed in conversation with your physician.
The takeaway
The UNITY study discontinuation confirms that efgartigimod will not proceed for this specific autoimmune indication based on current trial results. Patients should continue to monitor updates from their rheumatologists regarding emerging therapies and established management standards for Sjögren's disease.
Further reading
For broader context on current treatment challenges, visit the Arthritis section.
Live Poll
Do you trust pharmaceutical companies to prioritize patient health outcomes over successful clinical trial results?
